Albuquerque-based biotech company Nob Hill Therapeutics recently announced four new members of a "strategic advisory board," according to a November release from the company.
The four members of the new board are John Pritchard, Caroline Baxter, Charles Daley and Noel Greenberger.
Pritchard leads the board and is a consultant specializing in approaches to developing respiratory devices, among other things, according to a release from Nob Hill Therapeutics. Baxter is the clinical director of the National Aspergillosis Centre at Manchester University NHS Foundation Trust. Daley is a pulmonologist at the National Jewish Health, while Greenberger is chief commercial officer at Vertice Pharma, a manufacturer and distributor of generic pharmaceutical products, according to its website.
"[Nob Hill Therapeutics] has assembled a world-class advisory team," the company's CEO Yun Li said in a prepared statement. "The company is at an inflection point, the completion of the strategic advisory board is timely and much needed."
In addition to the new board, Nob Hill Therapeutics is raising its Series A round to further develop its "DryNeb" respirator product, according to the release. Nob Hill Therapeutics is seeking to raise $5 million for clinical-phase research, Business First reported in October.
Nob Hill Therapeutics aims to commercialize a nebulizer that provides powdered drugs to patients with more efficiency than current dry-powder nebulizers. The technology was developed at the University of New Mexico before being licensed by Nob Hill Therapeutics.
The startup, which is part of the VIC Technology Venture Development, is located at the BioScience Center at 5901 Indian School Road.
